STERIS's $600M Chemistry Bet: A Manufacturing Pivot in a Tariff-Clouded Quarter

The Formulated Chemistry Center of Excellence: A Strategic Inflection

STERIS's fiscal Q1 2027 call was less about the quarter's numbers — solid though they were — and more about a center of excellence that signals a deliberate shift in how the company intends to grow. The $600 million greenfield investment in North Carolina, the largest single-site manufacturing outlay in company history, will consolidate chemistry production from St. Louis and Plymouth into a highly automated, cleanroom-grade facility. CEO Dan Carestio framed it as a capacity necessity: "The problem is, is that neither are really expandable and both are going to be bumping up against the upper limits of capacity in the future" (“…neither are really expandable…” — Daniel Carestio, President and Chief Executive Officer · 2026-08-06). This is not a pivot to a new market but an intensification of a profitable niche — the high-margin, highly regulated chemistries that serve both healthcare and pharma customers.

The problem is, is that neither are really expandable and both are going to be bumping up against the upper limits of capacity in the future… this factory will be the factory of the future for us.

Management expects ROIC above 10% within three to five years of opening, and the consolidation promises greater automation and labor efficiency over time. The project, spread across three fiscal years with ~$350M in fiscal 2028, is a meaningful redeployment of the balance sheet firepower that had been earmarked for M&A. As Carestio noted on the prior call, "Any time there's a juxtaposition of manufacturing locations, we tend to benefit on the capital side of things" (“Any time there's a juxtaposition of manufacturing locations…” — Daniel A. Carestio, President and Chief Executive Officer (CEO) · 2026-02-05) — now STERIS is applying that logic to its own footprint.

Financial Discipline: Margins Firm Despite Tariff Fog

The quarter's financials showed resilience. Constant currency organic revenue grew 6%, with gross margin expanding 70 bps to 46% and EBIT margin up 100 bps to 23.8%. Gross tariff costs of $14M were partially offset by $4M in refunds, which management deliberately books to corporate to keep segment comparisons clean. CFO Karen Burton emphasized that underlying margin expansion was independent of tariff relief: “The gross margin is up absent tariffs... we got favorability from price productivity.” — Karen Burton, Senior Vice President and Chief Financial Officer · 2026-08-06 The company maintained FY27 EPS guidance of $11.10-$11.30 and organic growth of 6-7%, a steady outlook despite incremental tariffs remaining an ongoing drag. This discipline is visible in the fundamentals — total revenue hit $1.5B, up 7% y/y, and interest coverage sits at 18x, leaving ample room to fund the new facility while keeping the dividend growing for a 21st consecutive year.

The tariff refund mechanics are worth noting. The total potentially available is ~$27M, of which $24M is claimable under Phase 1/2; the company has submitted all claims but only recognized $4M so far. Karen's clarity on this accounting — excluding refunds from segment results — gives investors a cleaner read on operational performance.

Healthcare Resilience and the Endoscopy-Led Pull-Through

Healthcare delivered 6% organic growth, with consumables up 9% and services up 10%. The standout was endoscopy, where procedural growth and share gains are feeding demand for both dedicated chemistries and repair services. Carestio called out the shift toward earlier screening: "there’s been a change… about the early age of detection that has shifted down below 50 years… more people are eligible or being pulled in for endoscopies" (“…more people are eligible…” — Daniel Carestio, President and Chief Executive Officer · 2026-08-06). While Healthcare Capital grew only 1% in the quarter (a timing issue, with backlog up to $444M), the consumables pull-through from prior capital placements is building a resilient recurring base.

On the AST front, the company continues to weather customer inventory destocking, expecting acceleration in the second half as comparisons ease. This narrative has been consistent across recent quarters — as Carestio said back in November, "We continue to see pretty stable volume from our medtech customers…" (“We continue to see pretty stable volume…” — Daniel Carestio, President and CEO · 2025-11-06). The segment's 48% EBIT margin remains a powerful profit engine even with softer volumes. Operating margin reached 19.1% in the quarter, up 1.5pp year-over-year, helped by price, productivity, and favorable currency.

Overall, STERIS is executing a prudent balancing act: reinvesting heavily in a high-return niche while absorbing tariff noise and maintaining guidance. The stock sits ~14% below its January peak but has stabilized in the last 90 days, suggesting the market is waiting to see this investment translate into durable growth. With net debt/EBITDA at ~1.1x and a fortress balance sheet, the company has room to fund the build-out without sacrificing its buyback or dividend programs.